Abivax Aktie - ABVX

Abivax (ABVX) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

83,30

( -1,42% )

Gebot

82,00

Fragen

86,50

Volumen

127.974

81,55 Tagesbereich 87,35

57,50 52-Wochen-Bereich 128,40

Marktkapitalisierung

6,639B

Handelsende

84,50

Handelsbeginn

85,50

Letzte Trade

834

83.3

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

280.329 €

Ausgegebene Aktien

79.694.535

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-18,68

Gewinn pro Aktie (EPS)

-4,52

Erlöse (LTM)

4,92M

Nettogewinn (LTM)

-332,2M

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical devel... ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. Mehr anzeigen

Sektor

Healthcare

Branche

Biotechnology & Life Sciences

Website

www.abivax.com

Hauptsitz

Paris, France

Gegründet

2026

Abivax is listed in the Healthcare sector of the Euronext with ticker ABVX. The last closing price for Abivax was 84,50 €. Over the last year, Abivax shares have traded in a share price range of 57,50 € to 128,40 €.

Abivax currently has 79.694.535 shares in issue. The market capitalisation of Abivax is 6,64 € billion. Abivax has a price to earnings ratio (PE ratio) of -18.68.

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.05.26.

ABIVAX ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.05.26...

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère

ABIVAX Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to...

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26

ABIVAX ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26 29-Mai-2026 / 18:00...

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH

ABIVAX Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a...

Abivax annonce les résultats de son Assemblée Générale du 11 mai 2026

ABIVAX Abivax annonce les résultats de son Assemblée Générale du 11 mai 2026 11-Mai-2026 / 22:05 CET/CEST Information réglementaire transmise...

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm...

Abivax annonce le rachat des Certificats de Royalties et les modalités définitives de l’émission de 45M$ (38,5M€) d'American Depositary Shares

ABIVAX Abivax annonce le rachat des Certificats de Royalties et les modalités définitives de l’émission de 45M$ (38,5M€) d'American Depositary...

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-2.5	-2.91375291375	85.8	91.15	76.95	184476	83.11727757	DE
4	-30.9	-27.057793345	114.2	118.6	60.45	376927	79.42172138	DE
12	-20.8	-19.9807877041	104.1	118.6	60.45	308245	95.55243478	DE
26	-40.1	-32.4959481361	123.4	128.4	60.45	250809	99.33298779	DE
52	22.3	36.5573770492	61	128.4	57.5	186230	96.15201778	DE
156	67.56	429.224904701	15.74	128.4	4.51	79485	67.03639632	DE
260	52.9	174.013157895	30.4	128.4	4.51	58367	55.92366065	DE

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax share price?

The current share price of Abivax is 83,30 €

How many Abivax shares are in issue?

Abivax has 79.694.535 shares in issue

What is the market cap of Abivax?

The market capitalisation of Abivax is EUR 6,64B

What is the 1 year trading range for Abivax share price?

Abivax has traded in the range of 57,50 € to 128,40 € during the past year

What is the PE ratio of Abivax?

The price to earnings ratio of Abivax is -18,68

What is the cash to sales ratio of Abivax?

The cash to sales ratio of Abivax is 1,37k

What is the registered address of Abivax?

The registered address for Abivax is 7-11 Boulevard Haussmann, Paris, Ile-de-France, 75009

What is the Abivax website address?

The website address for Abivax is www.abivax.com

Which industry sector does Abivax operate in?

Abivax operates in the Biotechnology & Life Sciences sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Abivax (ABVX)

Abivax (ABVX) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Abivax

ABVX Neueste Nachrichten

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.05.26.

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax annonce les résultats de son Assemblée Générale du 11 mai 2026

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax annonce le rachat des Certificats de Royalties et les modalités définitives de l’émission de 45M$ (38,5M€) d'American Depositary Shares

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Provides 2026 Corporate Outlook

Abivax to be Added to Nasdaq Biotechnology Index

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

ABVX - Frequently Asked Questions (FAQ)

ABVX Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen